A multidimensional approach in testing nootropic drug effects (Cerebrolysin®)

Kofler, B; Erhart, C.; Erhart, Philipp; Harrer, G

doi:10.1016/0167-4943(90)90014-w

Cited by 16 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several clinical trials with Cerebrolysin in dementia patients support the assumption that cognitive disturbance is positively influenced 9,10,18,19 . However, to date, there are quite a few well‐controlled clinical trials of Cerebrolysin.…”

mentioning

confidence: 99%

A Double‐Blind, Placebo‐Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease

Bae

Cho

et al. 2000

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

A Double‐Blind, Placebo‐Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease

Bae

Cho

et al. 2000

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…Cerebrolysin acted as a presynaptic GABA B receptor agonist [794]. The nootropic effects of cerebrolysin were investigated in depth [795][796][797][798][799]. Cerebrolysin protected neurons from ischemia-induced loss of microtubule-associated protein 2 [800].…”

Section: Peptidesmentioning

confidence: 99%

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl

Pfeifer

Muhs

2013

JAD

View full text Add to dashboard Cite

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs, meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-β and tau. For drugs, whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. The review covers the evolution of research in this field over the last 25 years.

show abstract

“…5 Cerebrolysin is an extract of porcine brain containing a mixture of free amino acids and oligopeptides. 6 Randomized clinical trials addressed its safety and efficacy in several conditions like Alzheimer's disease 7 and traumatic brain injury. 8 One recent Cochrane review based on 6 trials evaluates the effects of cerebrolysin in acute ischemic stroke and concludes that the use of cerebrolysin has no effect on fatality.…”

Section: See Related Article P E245mentioning

confidence: 99%

Hope Dies Last—Evidence Again Fails to Support a Neuroprotectant

Bereczki

2017

Stroke

View full text Add to dashboard Cite

A multidimensional approach in testing nootropic drug effects (Cerebrolysin®)

Cited by 16 publications

References 15 publications

A Double‐Blind, Placebo‐Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease

A Double‐Blind, Placebo‐Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Hope Dies Last—Evidence Again Fails to Support a Neuroprotectant

Contact Info

Product

Resources

About